Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OVERVIEW OF MELANOMA VACCINES - ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA PATIENTS
Autore:
OLLILA DW; KELLEY MC; GAMMON G; MORTON DL;
Indirizzi:
ST JOHNS HLTH CTR,JOHN WAYNE CANC INST,SONYA VALLEY GHIDOSSI VACCINE LAB,2200 SANTA MONICA BLVD SANTA MONICA CA 90404 ST JOHNS HLTH CTR,JOHN WAYNE CANC INST,ROY E COATS RES LABS SANTA MONICA CA 90404
Titolo Testata:
Seminars in surgical oncology
fascicolo: 4, volume: 14, anno: 1998,
pagine: 328 - 336
SICI:
8756-0437(1998)14:4<328:OOMV-A>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTITUMOR IMMUNE-RESPONSES; CYTOLYTIC T-LYMPHOCYTES; PURIFIED GM2 GANGLIOSIDE; STAGE-III MELANOMA; TUMOR-BEARING MICE; B-CELL LYMPHOMA; METASTATIC MELANOMA; MALIGNANT-MELANOMA; DENDRITIC CELLS; CUTANEOUS MELANOMA;
Keywords:
MELANOMA; IMMUNOLOGY; CELLULAR IMMUNITY; IMMUNOTHERAPY; CANCER VACCINES; NEOPLASM ANTIGENS; NEOPLASM STAGING; CLINICAL TRIALS; COMBINED ANTINEOPLASTIC AGENTS; SURVIVAL RATE; SURVIVAL ANALYSIS; GANGLIOSIDES; INTERFERONS; DENDRITIC CELLS; IGG; IGM;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
72
Recensione:
Indirizzi per estratti:
Citazione:
D.W. Ollila et al., "OVERVIEW OF MELANOMA VACCINES - ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA PATIENTS", Seminars in surgical oncology, 14(4), 1998, pp. 328-336

Abstract

Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular response to a melanoma vaccine. The challenge of active specific immunotherapy research is to determine which combination of humoral and cellular immune responses optimizes clinical outcome and how to monitor the immune response effectively. This review identifies key components of a successful melanoma vaccine, discusses new ways to modulate and stimulate the immune system, and summarizes some ofthe important clinical trials of active specific immunotherapy for patients with melanoma. (C) 1998 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 00:38:15